C2N Diagnostics

Publication alert: Researchers report that C2N's %p-tau217 assay shows high accuracy in reflecting key brain changes linked to Alzheimer’s disease. The assay is a key component of the PrecivityAD2™ blood test that health care professionals use to help diagnose Alzheimer’s disease.

The research found strong correlations between the assay results and traditional neuropathological disease staging (Thal and Braak). They say the findings point to a potential precision medicine approach to disease-modifying therapies.

C2N generated the data in partnership with Han-Kyeol Kim and Hanna Cho of Yonsei University College of Medicine and Gangnam Severance Hospital.

Published in Alzheimer’s & Dementia - https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71199

There are many blood tests that can help health care professionals diagnose Alzheimer’s disease. How do you know which one is the best fit for you or your loved one?

Dr. Mark Monane (photo below), senior medical advisor to C2N Diagnostics, explained that C2N’s PrecivityAD2™ blood test includes multiple biomarkers that are highly associated with the presence of brain amyloid, the pathological hallmark of Alzheimer's disease.

In addition, Dr. Howard Fillit, 's Drug Discovery Foundation co-founder and chief science officer, called C2N’s test “the best,” while he also explained ADDF’s role as a supporter.

They spoke at ADDF’s “Tomorrow's Breakthroughs Today: Scientific Symposium Series.”

https://archive.ph/26Jw1

DiscoveryFoundation

We join the nation in recognizing today as Martin Luther King Jr. Day. Did you know it’s the only federal holiday designated as a National Day of Service, promoting acts of kindness and service?

Happy holidays from C2N Diagnostics!

Publication Alert: The Journal of Personalized Medicine recently published “Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.”

https://www.mdpi.com/2075-4426/15/10/469

Recent guidelines and workshop recommendations highlight the important role of Alzheimer’s disease (AD) blood tests in patient care. Real world implementation of these tests into clinical practice, however, has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2™ blood test (C2N Diagnostics) into the clinical workflow of memory care clinics.

The findings from this implementation study show that the PrecivityAD2 test was clinically useful, easy to incorporate into care, and associated with high health care professional (HCP) acceptance of the technology. As health systems pivot toward more effective diagnostic tools for facilitating AD diagnosis in clinical practice, the findings from this study provide valuable insights for the broader adoption of AD blood testing in personalized medicine and clinical practice settings.

Key Findings:
•Technology Assessment Model: Acceptance scores averaged 9.6 out of 10 (p < 0.0001, effect size 0.840); HCPs rated the test’s utility in “improving their diagnostic certainty,” “contribution to clinical decision-making,” and “ease of understanding test results” the highest among the attributes listed.
•Net Promoter Score (NPS): HCPs indicated excellent levels of trust and satisfaction for the test in their memory clinics with an NPS score of 75 (p < 0.0001) versus reference NPS score of 30, a benchmark value that is considered good in the healthcare setting. The extremely high NPS score from this study on the PrecivityAD2 test suggests that a significant majority of HCPs are likely to recommend the test to other HCPs.
•Coin Analysis/constant sum analysis: HCPs indicated that the test report’s APS2 result and the values of the two analyte ratios were of importance in their clinical decision-making, with 5.3 coins assigned to the APS2 result (53%) and 4.7 coins assigned to the analyte ratio values (47%).
•Open ended feedback from HCPs reinforced these observations for usefulness, ease of use and the test result reporting in clinical decision making.

Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. Howeve...

On Wednesday, November 5, Dr. Joel Braunstein, MD, CEO of C2N Diagnostics, will provide a keynote presentation on "A Moment in Medicine: Redefining Clinical Care in Alzheimer's Disease Through Precision Diagnostics” at the Rosalind Franklin University of Medicine
and Science in North Chicago, IL.
Registration information is included in the announcement below.

Our 4th annual Biomedical Innovation Day is coming up fast! Don't miss out on a fantastic networking and learning opportunity. Discover advances in brain health, with a keynote speech by Dr. Joel Braunstein, MD from C2N Diagnostics on "A Moment in Medicine: Redefining Clinical Care in Alzheimer's Disease Through Precision Diagnostics."

Register today and hear from an impressive lineup of RFU speakers and guest speakers from Rush Medical University, Healthcare Foundation of Northern Lake County, University of Illinois Chicago, Alzheimer's Association, UP Oncolytics, Inc, Vanqua Bio and Cures Within Reach. https://www.givecampus.com/schools/RosalindFranklinUniversity/events/rfu-s-4th-annual-biomedical-innovation-day